Nuvalent (NUVL) Net Equity Issued and Repurchased (2020 - 2026)
Nuvalent (NUVL) posted Net Equity Issued and Repurchased of $10.1 million for Q1 2026, down 97.98% on a QoQ basis from $500.6 million in Q4 2025, and up 122.55% year-over-year from $4.6 million in Q1 2025.
Nuvalent (NUVL) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Nuvalent's Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $10.1 million for Q1 2026.
- Quarterly Net Equity Issued and Repurchased rose 122.55% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $521.3 million (down 6.52% YoY) and the FY2025 annual result came in at $515.7 million, down 9.52% from the prior year.
- Net Equity Issued and Repurchased was $10.1 million for Q1 2026 at Nuvalent, down from $500.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $540.0 million in Q3 2024 and bottomed at $619000.0 in Q1 2023.
- A 4-year average of $109.5 million and a median of $5.8 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased soared 38804.9% — and 2025, when it tumbled 99.12%.
- Nuvalent's Net Equity Issued and Repurchased stood at $334.8 million in 2023, then slumped by 97.38% to $8.8 million in 2024, then surged by 5597.51% to $500.6 million in 2025, then tumbled by 97.98% to $10.1 million in 2026.
- Business Quant data shows NUVL's Net Equity Issued and Repurchased at $10.1 million in Q1 2026, $500.6 million in Q4 2025, and $4.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.14 Mn |
| Mar 31, 2026 | 10.14 Mn |
| Dec 31, 2025 | 500.64 Mn |
| Dec 31, 2025 | 500.64 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 8.79 Mn |
| Dec 31, 2024 | 8.79 Mn |
| Sep 30, 2024 | 540.00 Mn |
| Sep 30, 2024 | 540.00 Mn |
| Jun 30, 2024 | 4.29 Mn |
| Jun 30, 2024 | 4.29 Mn |
| Mar 31, 2024 | 6.45 Mn |
| Mar 31, 2024 | 6.45 Mn |
| Dec 31, 2023 | 334.81 Mn |
| Dec 31, 2023 | 334.81 Mn |